INTRODUCTION
============

In Japan, an education in the practice of traditional Japanese medicines was not popular in the standard educational system until recently. This circumstance may be due to the fact that the detailed mechanism(s) of the pharmacological action of traditional Japanese medicines, including rikunshito, remains unknown. Such mechanism(s) have been difficult to define, in part because traditional Japanese medicines usually incorporate a variety of components. As a result, many traditional medicines have been used empirically that is, for the treatment of specific symptom. For instance, the traditional Japanese medicine, kampo, often is prescribed (typically as combination therapy with modern Western practices) for patients with medically unexplained physical symptoms or intractable gastrointestinal (GI) symptoms. This patient group represents a distinct population compared to that of patients with more typical and milder symptoms. Therefore kampo therapy, like many traditional Japanese medicines falls within the field of experience-based medicine, in contrast to that of evidence-based medicine. However, evidence for the efficacy of traditional Japanese medicines, particularly for rikkunshito, continues to accumulate ([@B49]). Hence, this review covers both basic and clinical evidences of rikkunshito, including pharmacological functions and clinical efficacies for the treatment and management of disorders of the GI tract.

WHAT IS RIKKUNSHITO?
====================

Rikkunshito first appeared in the Japanese literature in the 1500s. This agent has since become one of most famous and prescribed medicines among the traditional medicines in Japan. Rikkunshito is composed of 8 constituents: *Glycyrrhizae* radix, *Zingiberis* rhizoma, *Atractylodis lanceae* rhizoma, *Zizyphi* fructus, *Aurantii nobilis* pericarpium, *Ginseng* radix, Pinelliae tuber, and *Hoelen* ([@B18]). In recent times, analysis of the components of rikkunshito has been actively performed using high performance liquid chromatography. This work revealed that rikkunshito contains several ingredients such as liquiritin apioside, liquiritin, liquiritigenin, isoliquiritin apioside, isoliquiritin, isoliquiritigenin, glycyrrhizin, narirutin, and hesperidin ([@B11]; Figure [1](#F1){ref-type="fig"}). Recently, hesperidin was shown to have the highest potency (among these components) in a model of gastric emptying delay. Together, these findings support the broad use of rikkunshito for patients with dysfunction of the upper GI tract, including abdominal bloating, discomfort, nausea, and anorexia.

![**Pharmacological actions of rikkunshito on gastric motility. (A)** Three dimensional analysis for rikkunshito by high performance liquid chromatography. **(B)** Effect of Rikkunshi-to on the decrease of the gastric emptying rate induced by L-NNA. **(C)** Effect of Rikkunshi-to on adaptive relaxation in isolated guinea pig stomachs. **(D)** Improvement in the 5-HT3 agonist \[1-(3-chlorophenyl)biguanide\]-induced delay in gastric emptying by rikkunshito.](fphar-06-00007-g0001){#F1}

BASIC PHARMACOLOGICAL FUNCTION OF RIKKUNSHITO: PROTECTIVE EFFECT ON MUCOSAL INJURIES AND PROKINETIC EFFECT ON GI MOTILITY
=========================================================================================================================

Gastric mucosa is sometimes injured by various factors such as ethanol, non-steroidal anti-inflammatory drugs, systemic stress, or *Helicobacter pylori* infection ([@B58]; [@B17]; [@B46]). Proton pump inhibitors (PPIs), histamine type 2 blockers, or mucoprotective agents are effective for treating such acute mucosal injuries ([@B3]; [@B61]). Thus, Western medical practices are sufficient for the treatment of such conditions. In addition to these conventional drugs, traditional Japanese medicines, including rikkunshito, also can protect against acute gastric mucosal injuries. Traditional Japanese medicines, including rikkunshito, are equality effective in treating ethanol-induced acute gastric mucosal injuries, through the amelioration of mucin content decrease of the gastric mucosa ([@B16]). Such effect is also partially mediated by nitric oxide (NO) but not by prostaglandins or sulfhydryls ([@B2]). Therefore, rikkunshito exerts protective effect against acute mucosal injuries in the rat model. However, there is no definitive evidence for this pharmacological function of rikkunshito under the acute and chronic conditions of the human stomach.

Gastric motility, a physiological function of the GI tract, generally consists of three phases: reservoir, churning, and emptying. The total coordination of these three phases is considered essential to healthy GI physiology. Among the three phases needed for gastric motility, gastric accommodation is considered to be the most important. Gastric accommodation provides the reservoir function, which originates in the proximal stomach and requires the activity of the neuronal transmitter NO ([@B8]; [@B56]). Rikkunshito is known to promote gastric accommodation in isolated guinea pig stomach ([@B19]). Rikkunshito also relaxes the smooth muscles at the fundus portion of stomach isolated from diabetic neuropathic rats with gastric dysmotility ([@B29]). The observed pharmacological functions also are induced by L-arginine, a substrate of NO synthase that is also a component of rikkunshito. Like prokinetic agents, rikkunshito counteracts the attenuation of gastric dysmotility resulting from inhibition of NO synthesis ([@B19]; [@B26]). Furthermore, rikkunshito attenuates the delay of gastric emptying mediated by the serotonin (5-HT) type 3 receptor, but does not counteract the delay caused by activation of dopamine receptors ([@B54]). Together, these findings indicate that rikkunshito can ameliorate gastric dysmotility mediated by NO or 5-HT pathways ([@B26]; [@B54]). Interestingly, rikkunshito enhances endogenous ghrelin levels in plasma, and regulates esophageal and gastric motilities ([@B45]; [@B60]). Ghrelin is known to have a strong orexigenic effect ([@B30]; [@B39]) and enhance GI motility ([@B14]; [@B22]; [@B62]). It also has reported that rikkunshito attenuates impairment of GI motility via dysfunction of ghrelin signaling in a rat model of gastroesophageal reflux disease (GERD; [@B37]). More recently, [@B38] extended this work to a model of gastric dysmotility. Those authors reported that acute restraint stress caused plasma acylated/desacyl ghrelin imbalance and gastric dysmotility in rat, and that exogenously administered acylated ghrelin relieved the gastric dysfunction caused by this stress. Rikkunshito was shown to enhance endogenous ghrelin signaling and to provide similar relief of stress-induced gastric dysmotility ([@B38]). In a model of reflux esophagitis (RE), rikkunshito also inhibited the activation of ERK1/2 and decreased substance P and calcitonin gene-related peptide (CGRP) levels in Th8--10 dorsal root ganglia ([@B31]). This finding may indicate that rikkunshito inhibits afferent neuronal activity associated with visceral pain, ameliorating decreased voluntary movement in this model. Together, these research data suggest that rikkunshito may be a promising drug for the treatment of GERD and functional dyspepsia (FD) in the clinic; this medicine's activity presumably is mediated by its pharmacological effects on esophageal and gastric motilities (Figure [1](#F1){ref-type="fig"}).

CLINICAL EFFICACIES OF RIKKUNSHITO FOR UPPER GI SYMPTOMS
========================================================

TREATMENT WITH RIKKUNSHITO FOR GERD
-----------------------------------

The prevalence of obesity and metabolic syndrome in Japan continues to rise. At the same time, the rate of *H. pylori* infection in Japan is on the decrease. Under these circumstances, the prevalence of GERD is expected to increase in Japan, as has been seen in Western countries ([@B15]; [@B13]). The reflux of gastric contents, consisting primarily of gastric acid, is reported to be principal source of the pathogenesis of GERD ([@B57]). Additionally, transient lower esophageal sphincter relaxation (TLESR) also is recognized to be critical to the pathogenesis of GERD ([@B20]). Further GERD-associated factors include esophageal dysmotility, hypersensitivity to gastric acid or bile acid within the lower part of the esophagus, and gastric dysmotility affecting gastric accommodation and emptying. PPIs have been established as among the most effective drugs for treatment of GERD ([@B7]). However, other drugs regulating the esophageal motor functions also may prove useful in GERD treatment. Based on the above-described data on rikkunshito, the agent is a potential candidate treatment for patients with GERD, and so has been the subjects of clinical research. In a study that used pH multichannel intraluminal impedance monitoring, rikkunshito increased esophageal clearance and decreased esophageal acid exposure time, yielding relief of nausea symptoms in children with GERD ([@B25]). This traditional medicine also has been reported to relieve heartburn and acid regurgitation ([@B21]).

In our own clinical work, we often encounter adult patients with PPI-refractory GERD, although PPIs typically are very effective for treating this disease. Anecdotally, PPI-refractory GERD often is observed in patients lacking erosions of the esophageal mucosa (non-erosive reflux disease, NERD). In the GERD 4 study (a randomized, parallel comparative study of PPI-refractory patients with GERD), combined treatment with rikkunshito and standard-dose rabeprazole showed an efficacy similar to that of double-dose PPI treatment ([@B52]). In a subsequent study (G-PRIDE: A randomized, placebo-controlled, double-blind clinical trial of rikkunshito for patients with NERD refractory to PPI), rikkunshito improved psychological quality of life (QOL) compared to the placebo control ([@B53]). In addition, among secondary endpoints, significant efficacy of rikkunshito was observed for acid-related dyspeptic symptoms, especially among non-obese patients, women, and the elderly. Subclass analysis of the elderly PPI-refractory NERD patients in the G-PRIDE study also showed that rikkunshito significantly improved total and acid-related dysmotility scores after the 8-week treatment interval compared to placebo. In addition, 8-week combination therapy with rikkunshito significantly improved symptoms of abdominal bloating, "heaviness" of the stomach, sick feeling after meals, and heartburn after meals ([@B42]). Beyond standard symptoms, patients with GERD also are known to exhibit extra-esophageal symptoms. Interestingly, rikkunshito has been shown to be effective for patients with globus sensation, an effect mediated by attenuation of delayed gastric emptying ([@B48]).

On the other hand, rikkunshito also has activities distinct from prokinetic functions. In a rat RE model, rikkunshito was shown to promote tight junction protein formation and to contribute to the repair of the dilation of intercellular spaces in the epithelial mucosa ([@B35]). As with gastric acid, bile acid reflux is important for mucosal hypersensitivity in the pathogenesis of PPI-refractory GERD. Rikkunshito is reported to exhibit potent and differential absorption of bile salts ([@B4]). Notably, these findings suggest that rikkunshito may attenuate mucosal hypersensitivity to gastric acid or bile acid. These distinct pharmacological functions of rikkunshito may be a mechanism for relief of GERD symptoms in PPI-refractory NERD patients. Currently, long-term maintenance and enhanced therapies are recommended as future therapeutic regimens for PPI-refractory GERD patients ([@B28]). Based upon these evidences, treatment regiments incorporating rikkunshito may be beneficial to GERD patients, particularly for PPI-refractory cases. (Figure [2](#F2){ref-type="fig"}).

![**Pharmaceutical efficacies of rikkunshito for GERD treatment**.](fphar-06-00007-g0002){#F2}

TREATMENT WITH RIKKUNSHITO FOR FD
---------------------------------

Functional dyspepsia presents as symptomatic gastritis. Pathogenesis of this disease is similar to that of chronic gastritis associated with *H. pylori* infection. Therefore, FD recently has been categorized as a disease distinct from chronic gastritis, and therefore has been classified as a member of the functional gastrointestinal disorders (FGIDs). According to the 2006 Rome III criteria ([@B9]), the diagnosis of FGIDs is indicated in FD patients exhibiting any of four symptoms (epigastric pain, epigastric burning, postprandial fullness, or early satiety) originating from the gastroduodenal tract without evident organic injuries. These symptoms often persist even after a variety of treatments, decreasing the QOL in patients with FD ([@B27]). The pathophysiology of FD can reflect disorders of GI motility ([@B51]), acid secretion ([@B10]; [@B23]), visceral hypersensitivity ([@B12]), *H. pylori* infection ([@B36]), psychological factors ([@B50]; [@B40]), and imbalance of the autonomic nervous system (ANS; [@B41]). Of these factors, GI dysmotility has been most frequently associated with the pathogenesis of FD; however, this emphasis may reflect the relative ease of evaluating the physiological function of the GI tract in patients with FD. Gastric motility, notably its delay, has been a focus of evaluation in the pathogenesis of FD ([@B6]). However, total coordination of gastric motility needs to be further elucidated for its potential role in the pathogenesis of FD. Indeed, disorder of gastric accommodation may cause epigastric discomfort, early satiety, and bloating in patients with FD ([@B5]). Previously, we have reported that the impairment of gastric accommodation is associated with a delay in gastric emptying, resulting in dyspeptic symptoms ([@B51]). Recently, the high efficacy of acotiamide was demonstrated for treatment of dyspeptic symptoms in FD patients, an effect mediated by improvement of gastric accommodation ([@B34]; [@B33]). Based on the results of various clinical trials, only acid suppressant drugs, prokinetic drugs, and eradication therapy for *H. pylori* have (until recently) been strongly recommended in Japan for treatment of FD. In this context, rikkunshito has been reported to ameliorate the delay in gastric emptying in patients with non-ulcer dyspepsia (NUD; [@B47]). The same report indicated that rikkunshito also alleviated various upper GI symptoms in patients with NUD ([@B47]). Moreover, rikkunshito has demonstrated efficacy for attenuation of impaired gastric accommodation and gastric motility ([@B32]). Separate from stress' effects on gastric motility in the pathogenesis of FD, physical and psychological stresses often cause gastric hypersensitivity to stimulation by mechanical balloon distension. Stress-induced gastric hypersensitivity and/or changes in gastric wall tone (as assessed by gastric barostat method) were relieved by rikkunshito ([@B43]). In a separate human study comparing rikkunshito and domperidone, rikkunshito improved symptoms of patients with FD and increased plasma ghrelin levels ([@B1]). Rikkunshito was shown to ameliorate delayed gastric emptying in severely handicapped patients ([@B24]) and to improve gastric myoelectric activity in post-operative dyspeptic children after GI surgery ([@B59]). These findings suggest that rikkunshito affects some inflammatory and/or neuroendocrinal mediators as well as gastric sensorimotor function, and improves dyspeptic symptoms of FD. Apart from FD, GI symptoms sometimes occur after endoscopic treatment. Combination therapy with rikkunshito and PPI after endoscopic submucosal dissection alleviated abdominal pain symptoms ([@B55]). Recently, a randomized clinical trial using rikkunshito was performed for FD. Eight-week treatment with rikkunshito was tended to be effective for FD, as determined by global patient assessment ([@B44]). Thus, rikkunshito is a potential candidate for the clinical treatment of FD.

In conclusion, rikkunshtio is considered "complementary" (non-mainstream) medicine for treatment of GI diseases such as GERD and FD. However, rikkunshito frequently is prescribed for patients with diverse GI tract disorders. Combination treatments using modern Western and traditional Japanese medicines should be considered, especially in patients presenting with intractable symptioms, including general malaises.
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